Bubs Australia: Tariff and Regulatory Headwinds Mask Underlying Growth

Bubs Australia enters FY27 with a familiar story: a small-cap dairy player that has outgrown its home market, but now must navigate a bewildering array of external shocks. The FY26 results, delivered by CEO Joe Coote, show a company that is still growing — “We've delivered just shy of $112 million of revenue. That's up 9% across the group, but very pleasingly up 24% in the U.S.” — Joe Coote, Chief Executive Officer · 2026-08-26 Yet the bottom line tells a more complicated tale. Reported EBITDA came in at -$1.8M, but that includes $2.6M in tariff costs, ~$4M in regulatory reset expenses, and $3M in airfreight — all called out as one-offs. Underlying EBITDA of $5.3M, up from the prior year, suggests the core business is healthier than the headline suggests.

The Tariff and Regulatory Tag-Team

The most striking theme this quarter is regulatory reset — a term used repeatedly, and one that captures the global disruption to product flows. "We've navigated a regulatory reset. Now this has been a global reset and that started on the 5th of January." That reset, combined with a U.S. tariff regime that shifted multiple times, forced Bubs to spend aggressively to protect shelf presence. As CFO Chris Rowe explained, the company is the importer of record: “Bubs is actually the importer into the United States... we have to pay whatever tariffs, custom duties, fees and the like to bring that product into United States.” — Chris Rowe, Chief Financial Officer · 2026-08-26 The company is pursuing refunds where possible, but CFO Rowe noted exposure to subsequently-deemed-illegal tariffs was "quite small." This puts Bubs in a different position from many U.S.-based reporters in the same quarter who are booking refunds; Bubs is absorbing costs, not receiving credits.

The regulatory reset also triggered inventory write-offs and a deliberate rebuild. Inventory rose from $20M to $36.3M, funded by cash and debt. The company frames this as necessary to support growth, given the 4-6 month supply chain lead time. The write-downs are included in the ~$4M regulatory cost bucket, and management expects these to be largely one-time.

So we protected our consumers. We've taken those write-downs and the flows are returning to normal now with the resets that we've seen from the regulators in the different markets around the world.

U.S. Beat, China Builds, Australia Rebuilds

Geographically, there's a clear divergence. The U.S. is now 59% of revenue, with distribution across 10,000+ stores in all 50 states, and the company is expanding into new formats like Sam's Club. The premium-natural and goat subsegments are bright spots: goat category share stands at 20%, a niche with no domestic U.S. production. The company is investing heavily in marketing — up 21% year-over-year — and leveraging platforms like TikTok and Reddit. "Our click-through rate on Amazon is up 20%," Coote said, offering a tangible sign of brand momentum.

China, second at ~19% of revenue, is being repositioned. The business in China saw sell-out growth over 30% in both O2O and CBEC channels as the company worked through inventory imbalances. The adult milk brand CapriLac is an emerging growth vector, with a China-label product now in 100 premium retail outlets. But Coote candidly noted the competitive cost of activation in China: "It's a little bit like Uber surge pricing. We've been in surge pricing mode in China for a little while now." Still, he reiterated China remains a key growth market.

Australia, at 16% of revenue, is the laggard. Management acknowledged disappointment but pointed to green shoots: brand awareness up 10 points and market share regaining in H1 FY27. The clean label positioning and 'proudly Australian' narrative are central to that recovery, along with a stepped-up advertising promotion spend in the second half.

FDA and the Strategic Horizon

The most awaited catalyst is the FDA approval for permanent U.S. market access. After over four years of engagement, including an infant growth study and physical facility audits, management says they are in the final review stage: “We have progressed significantly. We are in the final review stage and we are very confident that we will receive the FDA notification.” — Joe Coote, Chief Executive Officer · 2026-08-26 This is a binary event that could unlock a step-change in U.S. growth, but also carries risk. The company is already operating in the U.S. under temporary tariff arrangements, so approval would reduce regulatory overhang.

Strategically, Bubs has laid out three pillars: activate the brand, build winning portfolios, and connect farms to families. The winning portfolio includes innovations in adult nutrition and potential Canada entry. The company has also committed to expanding its goat herd by 70% to secure supply. While the stock is small (market cap ~$75M), the story is not static — the company is executing on a plan that blends organic growth, offshore expansion, and regulatory resolution.

For investors, the key question is whether the one-off costs truly are one-off. The inventory rebuild is largely complete, airfreight has ceased, and the regulatory reset is normalizing. If tariff refunds or FDA approval materialize, the operating leverage could be significant. The market's muted reaction (no price tape available) suggests caution, but the underlying progress is real. Bubs is a niche player in a premium segment, and FY27 is a year where execution, not external shocks, should take center stage.

In a quarter where global earnings calls were dominated by tariff refunds and regulatory uncertainty, Bubs stands out as a company that is paying tariffs — not collecting them — and navigating a different kind of reset. Its ability to maintain gross margins while absorbing these costs hints at pricing power. With the strategic groundwork laid, the inflection point may be closer than the headline loss suggests.